5 Key Takeaways

• 1

  Ustekinumab-aekn (Selarsdi) is approved for all indications of the reference product, including psoriasis and Crohn’s disease.

• 2

  The FDA approved the ustekinumab biosimilar as interchangeable with the reference biologic ustekinumab (Stelara).

• 3

  The biosimilar is produced using Sp2/0 cells and a continuous perfusion process, similar to the reference biologic.

• 4

  The safety profile of the ustekinumab biosimilar is consistent with the reference product, including risks for serious infections.

• 5

  The ustekinumab biosimilar is contraindicated in patients with known hypersensitivity to ustekinumab or its excipients.